Bioo Scientific company information, Employees & Contact Information

GSK pens $745M deal for phase 1 drug that hits sweet spots of COPD, oligonucleotides Fierce Biotech

GSK pens $357M pact with French biotech for prostate cancer ADC Fierce Biotech

MapLight goes public via $250M IPO to fund Cobenfy competitor Fierce Biotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized Fierce Biotech

Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity Fierce Biotech

Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T deal Fierce Biotech

BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence Fierce Biotech

Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners Fierce Biotech

Eli Lilly and Nvidia team up to build 'most powerful' supercomputer in pharma Fierce Biotech

Edesa claims survival data win for phase 3 respiratory failure trial Fierce Biotech

WuXi AppTec sharpens focus by selling off China-based clinical research units Fierce Biotech

Aldeyra shuffles RASP pack, dropping and swapping assets in response to data Fierce Biotech

Labcorp posts solid Q3 results but trims full-year revenue forecast Fierce Biotech

AbbVie, Regeneron and Sanofi help fund $80M series A round for Tregs specialist Zag Bio Fierce Biotech

Convatec report finds 'widespread social stigma' tied to chronic conditions Fierce Biotech

Lonza to buy rapid microbial testing firm Redberry SAS Fierce Biotech

Incyte scraps BET inhibitor against backdrop of safety concerns for the drug class Fierce Biotech

Jupiter Endovascular's Vertex TFX catheter platform study shows positive results Fierce Biotech

2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners Fierce Biotech

De-Risking Clinical Development: Strategic Multipliers in Global Trials Fierce Biotech

BridgeBio aces phase 3 rare disease test, clearing path to FDA Fierce Biotech

Zenas' autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study Fierce Biotech

Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions Fierce Biotech

Lilly buys cash-strapped Adverum for eye disease gene therapy Fierce Biotech

Redefining Biotech: How AI and Real-World Data Power Patient-Centered Progress Fierce Biotech

Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs Fierce Biotech

Novo shutters cell therapy unit, ending work on potential Type 1 diabetes 'cure' Fierce Biotech

After high-profile FDA exit, Peter Marks lands at Eli Lilly Fierce Biotech

Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight Fierce Biotech

Sanofi inks pact with Canadian tech company to bring AI to R&D Fierce Biotech

Flagship taps IQVIA as biotech support for company fleet Fierce Biotech

UPDATED: Takeda lays off 137 US staff as part of retreat from cell therapy Fierce Biotech

After a 'complete standstill,' private biotech market reaches new normal, investor says Fierce Biotech

James Mackay is tending to 'unfinished business' with new gout biotech and $205M fundraise Fierce Biotech

Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review Fierce Biotech

Introducing Fierce Biotech's 2025 Fierce 15 Fierce Biotech

Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT Fierce Biotech

US may be denying R&D grants for biotechs based on international investor links Fierce Biotech

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal Fierce Biotech

Eli Lilly reconsiders UK biotech incubator, pauses buildout Fierce Biotech

Genentech scraps $2B deal with cell therapy biotech Fierce Biotech

Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs Fierce Biotech

China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies report Fierce Biotech

Regeneron reports key phase 3 win in myasthenia gravis, gears up for FDA filing Fierce Biotech

Sitala, backed by Forbion and OrbiMed, seals $670M deal for Fosun immune disease drug Fierce Biotech

Amgen to build $600M R&D site, hire hundreds in California Fierce Biotech

CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit Fierce Biotech

Trinity Biotech reports its 15-day CGM works without fingersticks Fierce Biotech

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal Fierce Biotech

Biopharma layoffs for first half of the year jump 32% YOY Fierce Biotech

Xoma adds fading Mural Oncology to portfolio of struggling biotechs Fierce Biotech

Bayer picks Kumquat for KRAS collaboration, with $1.3B on offer if pact bears fruit Fierce Biotech

VantAI plays matchmaker for Halda's 'hold-and-kill' drugs in $1B deal Fierce Biotech

Cell therapy biotech Adicet turns to autoimmune, shedding a phase 1 asset and 30% of staffers Fierce Biotech

Enveda harvests another $150M to advance nature-inspired drugs Fierce Biotech

FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub Fierce Biotech

Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY Fierce Biotech

China proposes shorter clinical trial reviews in efforts to accelerate drug development Fierce Biotech

Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy Fierce Biotech

UPDATE: Analyst questions impact of FDA's rare disease pathway proposal Fierce Biotech

Vedanta's live bacteria cocktail fails to reduce ulcerative colitis severity in phase 2 trial Fierce Biotech

Merck executes its own Brexit, moving all R&D operations out of UK Fierce Biotech

ARPA-H data chief departs over disagreement with mRNA vaccine rollback Fierce Biotech

Lilly rounds out oral GLP-1 approval bid with phase 3 obesity win for patients with diabetes Fierce Biotech

Gilead culls Novo-partnered MASH candidate and 2 cancer assets Fierce Biotech

Merck KGaA swoops into Skyhawk neurological disease pact worth up to $2B Fierce Biotech

'America-first resurgence': Amid market correction, biotech nears new era, PitchBook says Fierce Biotech

2025 Fierce CRO Awards Fierce Biotech

Sanofi-backed SpliceBio secures $135M series B for eye disease gene therapy trials Fierce Biotech

Cell therapy biotech shares first clinical data for in vivo CAR-T that attracted $1B AstraZeneca acquisition Fierce Biotech

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal Fierce Biotech

Sanofi phase 3 eczema win falls short of analyst expectations Fierce Biotech

Medtronic expands board to chase M&A, efficiencies as activist investor takes stake Fierce Biotech

Avantor comes under pressure from activist investor Engine Capital Fierce Biotech

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Fierce Biotech

TCG Labs Soleil raises $400M for single-asset biotechs, expands R&D footprint to China Fierce Biotech

Pfizer expands AI-powered small-molecule discovery collab with XtalPi Fierce Biotech

Bristol Myers inks $11B BioNTech deal to join bispecific gold rush, leaping ahead of Merck and Pfizer Fierce Biotech

Eli Lilly pays $1B upfront to buy gene editing partner Verve Therapeutics Fierce Biotech

GSK strengthens COPD offering via $12B biobucks, 12-program deal with China's Hengrui Pharma Fierce Biotech

AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market Fierce Biotech

Fierce Biotech Layoff Tracker 2025: Alector halves staff; Galapagos axes cell therapy unit Fierce Biotech

FDA misses IND deadline for Coya's ALS asset, cites lack of resources Fierce Biotech

Congressional commission urges $15B, more action to maintain US biotech advantage over China Fierce Biotech

Alphabet's Calico stitches $596M deal for Mabwell's anti-aging asset Fierce Biotech

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication Fierce Biotech

Aiming to disrupt the cardiovascular space, 2 industry vets unveil Boston biotech with preventive RNAi asset Fierce Biotech

Roche’s Chugai inks $250M Gero deal to access age-related disease targets Fierce Biotech

RA Capital's biotech incubator lays off staffers: Stat Fierce Biotech

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug Fierce Biotech

J&J ties early-stage lymphoma CAR-T to 100% response rate in 10 patients Fierce Biotech

Months after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60M Fierce Biotech

The top 10 pharma R&D budgets for 2024 Fierce Biotech

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M Fierce Biotech

Several months after Exscientia merger, AI biotech outfit Recursion reworks pipeline Fierce Biotech

Verve's 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision Fierce Biotech

ProKidney’s CKD cell therapy scores win in one half of phase 2 trial, falls short on other Fierce Biotech

Anti-aging biotech NewLimit raises $130M to push liver reprogramming med into clinic Fierce Biotech

Fierce Biotech Fundraising Tracker '25: Hemab closes $157M series C; Electra shines with $183M Fierce Biotech

Kymera suffers Sanofi setback but secures $750M Gilead deal Fierce Biotech